Gentium Spa (AMEX:GNT)
Historical Stock Chart
From Jun 2019 to Jun 2024
Gentium S.p.A. (AMEX:GNT) (the "Company") announced
today that Laura Ferro, M.D., Chairman and Chief Executive Officer of
Gentium, will present a corporate update at the upcoming Rodman &
Renshaw Techvest Seventh Annual Healthcare Conference. The
presentation is scheduled for 11:15 a.m. (Eastern Time) on Wednesday,
November 9, 2005. The event will be held from November 7-9, 2005 at
the New York Palace Hotel in New York.
Individuals may listen to a live web cast of the presentation by
logging on to the Investor Relations section of the Company's web site
at www.gentium.it a few minutes prior to the start time to download
any necessary software. The presentation will be archived for a
limited time. The Company's updated investor presentation can also be
viewed at the Investor Relations section of the Company's web site.
The conference will feature presentations from more than 290
public and privately held emerging growth healthcare companies
presenting data on an array of therapeutic topics including oncology,
cardiovascular disease, central nervous system disorders, infectious
diseases and medical device technology. Details regarding the
conference can be obtained at www.rodmanandrenshaw.com.
About the Company
Gentium S.p.A. is a biopharmaceutical company located in Villa
Guardia (Como), Italy that is focused on the research, discovery and
development of drugs derived from DNA extracted from natural sources,
and drugs which are synthetic derivatives, to treat and prevent a
variety of vascular diseases and conditions related to cancer and
cancer treatments. Defibrotide, the Company's lead product candidate
in the U.S., is an investigational drug that has been granted Orphan
Drug status by the U.S. FDA to treat veno-occlusive disease (VOD) with
multiple organ failure ("Severe VOD") and Fast Track designation for
the treatment of Severe VOD in recipients of stem cell transplants.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In some
cases, you can identify these statements by forward-looking words such
as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential" or "continue," the
negative of these terms and other comparable terminology. These
statements are not historical facts but instead represent the
Company's belief regarding future results, many of which, by their
nature, are inherently uncertain and outside the Company's control. It
is possible that actual results may differ, possibly materially, from
those anticipated in these forward-looking statements. For a
discussion of some of the risks and important factors that could
affect future results, see the discussion in our Prospectus filed with
the Securities and Exchange Commission under Rule 424(b)(4) under the
caption "Risk Factors."